Table 1.
Characteristics of donor cohorts
| COVID-19 (n = 28) | Vaccinees (n = 29) | Unexposed (n = 23) | |
|---|---|---|---|
| Age, y | 20–67 (median = 38, IQR = 32) | 23–67 (median = 47, IQR = 36) | 21–82 (median = 34, IQR = 24) |
| Gender, % | |||
| Male | 43 (12/28) | 31 (9/29) | 35 (8/23) |
| Female | 57 (16/28) | 69 (20/29) | 56 (13/23) |
| Unknown | 0 (0/28) | 0 (0/29) | 9 (2/23) |
| Sample collection date | May–October 2020 | January–March 2021 | May 2014–March 2018 (13/23) |
| March–May 2020 (10/23) | |||
| SARS-CoV-2 PCR, % | positive 92 (12/13) | N/A | N/A |
| not tested 54 (15/28) | |||
| S RBD IgG+ (%) | 96 (27/28) | 100 (29/29) | 0 (10/10, collected in 2020) |
|
Peak disease severity, %a | |||
| Mild | 86 (24/28) | N/A |
N/A |
| Moderate | 14 (4/28) | ||
| Severe | 0 (0/28) | ||
| Critical | 0 (0/28) | ||
| Race-ethnicity, % | |||
| White—not Hispanic or Latino | 81 (23/28) | 52 (15/29) | 43 (10/23) |
| Hispanic or Latino | 4 (1/28) | 10 (3/29) | 9 (2/23) |
| Asian | 7 (2/28) | 38 (11/29) | 26 (6/23) |
| American Indian/Alaska Native | 0 (0/28) | 0 (0/29) | 0 (0/23) |
| Black or African American | 0 (0/28) | 0 (0/29) | 9 (2/23) |
| >1 race | 4 (1/28) | 0 (0/29) | 4 (1/23) |
| Not reported | 4 (1/28) | 0 (0/29) | 9 (2/23) |
| Days at collection | 38–163 (28/28) (median = 78, IQR = 50)b | 13–30 (14/29) Pfizer | N/A |
| 12–16 (15/29) Moderna (median = 14, IQR = 14)c | |||
a
According to World Health Organization criteria.
b
Post-symptom onset.
c
2nd dose of vaccine.